VEL 0230
Alternative Names: NC-2300; VEL-0230Latest Information Update: 08 Feb 2011
At a glance
- Originator Nippon Chemiphar
- Developer Velcura Therapeutics
- Class Anti-inflammatories; Antirheumatics; Osteoporosis therapies; Small molecules
- Mechanism of Action Osteoclast inhibitors; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple myeloma; Osteoporosis; Rheumatoid arthritis
Most Recent Events
- 08 Feb 2011 No development reported - Phase-I for Multiple myeloma in USA (PO)
- 08 Feb 2011 No development reported - Phase-I for Osteoporosis in USA (PO)
- 08 Feb 2011 No development reported - Phase-I for Rheumatoid arthritis in USA (PO)